N/A
Manufactured by Pharmacia & Upjohn Company LLC
23,035 FDA adverse event reports analyzed
Last updated: 2026-04-14
IRINOTECAN HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Pharmacia & Upjohn Company LLC. The most commonly reported adverse reactions for IRINOTECAN HYDROCHLORIDE include DIARRHOEA, OFF LABEL USE, NAUSEA, DEATH, VOMITING. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for IRINOTECAN HYDROCHLORIDE.
Out of 12,001 classified reports for IRINOTECAN HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 23,035 FDA FAERS reports that mention IRINOTECAN HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DIARRHOEA, OFF LABEL USE, NAUSEA, DEATH, VOMITING, DISEASE PROGRESSION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Pharmacia & Upjohn Company LLC in connection with IRINOTECAN HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.